BCC - Basal Cell Carcinoma
7
2
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Effectiveness and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
The Diagnostic Accuracy of Advanced Imaging in Identifying Suspected Skin Cancer (Basal Cell Carcinoma) Around the Eyes
Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma
L19IL2/L19TNF in Skin Cancer Patients
CellFX Treat & Resect Low-Risk BCC Feasibility Study
Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas